Results 171 to 180 of about 213,311 (303)
Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. [PDF]
Liu X, Lu CA, Shih YT, Jiang C.
europepmc +1 more source
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu +13 more
wiley +1 more source
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley +1 more source
ABSTRACT Objective This study examined the relationship between health‐related quality of life (HRQoL) and weight status across the pediatric life course. Methods We analyzed data from a cohort of 9745 children from the Longitudinal Study of Australian Children, with follow‐up over 14 years.
Alison Hayes +4 more
wiley +1 more source
Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications
ABSTRACT Objective This study compared changes in health care costs and use across cohorts initiating four obesity medications (OMs). Methods Commercial insurance claims were used to identify new initiators of phentermine (n = 136,788), phentermine‐topiramate‐ER (n = 13,888), naltrexone‐bupropion‐SR (n = 28,712), or liraglutide (n = 49,266) for obesity.
Kristina H. Lewis +10 more
wiley +1 more source
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez +10 more
wiley +1 more source
Medicare Part D Formulary Coverage of Disease-Modifying Therapies for Multiple Sclerosis.
Li P +5 more
europepmc +1 more source
Medicare Part D Preferred Pharmacy Networks And The Risk For Pharmacy Closure, 2014-23. [PDF]
Guadamuz JS +3 more
europepmc +1 more source
Abstract Free flap procedures are important components of reconstructive surgery in otolaryngology, plastic surgery, and maxillofacial surgery. This research investigates trends in utilization, charges, and Medicare reimbursements for free flap procedures performed across these specialties.
Kyle Polen +4 more
wiley +1 more source
Potential Cost Savings in Medicare Part D for Otolaryngologic Medications. [PDF]
Tripathi OB +6 more
europepmc +1 more source

